THC:CBD Extract Modestly Eases Subjective MS Spasticity

This systematic review with network meta-analysis clarifies that among cannabinoid formulations, only standardized THC:CBD extract shows consistent, though modest, benefit on patient-reported multiple sclerosis spasticity, informing formulary and counseling decisions.

📅 Journal publication: Aug 4, 2026 · Last updated: Oct 8, 2026

nabiximolsTHC:CBDcannabidioltetrahydrocannabinoldronabinolnabilonecannabinoidsmultiple sclerosisspasticitynetwork meta-analysissystematic reviewneurology Neurology / Neuropharmacology

Background Information

Antidiabetic drug safety profiles expand significantly post-marketing.

Understanding the safety profiles of antidiabetic medications is crucial for making informed treatment decisions in type 2 diabetes mellitus. The study identified 326 unique safety outcomes for 27 antidiabetics, with notable increases in post-marketing outcomes for SGLT-2 inhibitors and GLP-1 receptor agonists. The findings highlight the evolution of safety data over time, emphasizing the need for clinicians to continually update their knowledge of antidiabetic drug safety. Safety profiles for antidiabetic drugs expand post-marketing, necessitating continual clinician awareness.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Liang D, Weir DL, Thevasahayam S, Deneer VHM, Siebes A, Gardarsdottir H

Citation: Liang D, Weir DL, Thevasahayam S, et al. Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines. British journal of clinical pharmacology. 2026. doi:10.1002/bcp.70733

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →